Has Arena Pharmaceuticals Become the Perfect Stock?

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Arena Pharmaceuticals (NASDAQ: ARNA  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Arena Pharmaceuticals.

Factor

What We Want to See

Actual

Pass or Fail?

Growth

5-year annual revenue growth > 15%

7.3%

Fail

 

1-year revenue growth > 12%

89.2%

Pass

Margins

Gross margin > 35%

83%

Pass

 

Net margin > 15%

NM

NM

Balance sheet

Debt to equity < 50%

63.8%

Fail

 

Current ratio > 1.3

9.34

Pass

Opportunities

Return on equity > 15%

(115.3%)

Fail

Valuation

Normalized P/E < 20

NM

NM

Dividends

Current yield > 2%

0%

Fail

 

5-year dividend growth > 10%

0%

Fail

       
 

Total score

 

3 out of 8

Source: S&P Capital IQ. NM = not meaningful due to substantial negative earnings in excess of revenue. Total score = number of passes.

Since we looked at Arena Pharmaceuticals last year, the company has gotten back the point it lost from 2011 to 2012, as revenue growth perked up. But shareholders couldn't be happier, as the stock has climbed more than 400% over the past year.

The big news for Arena in 2012 was the Food and Drug Administration's approval of its Belviq anti-obesity drug over the summer. Unfortunately for the company, though, the Drug Enforcement Agency has to provide a classification for the drug before Belviq can become available to patients. That delay has allowed VIVUS (NASDAQ: VVUS  ) and its rival Qsymia drug to get a jump on Arena, but Arena has set up a better distribution and marketing network and should be able to get approval in Europe -- something that eluded Qsymia.

But Arena could soon face even more competition beyond VIVUS. The FDA forced Orexigen (NASDAQ: OREX  ) to run an additional trial of its Contrave obesity drug to test for heart risks, and with that trial slated to provide interim results as early as this year's second quarter, positive results could mean another entrant into the growing space. In addition, Amgen (NASDAQ: AMGN  ) has had some success with a fat-fighting antibody that could eventually evolve into an obesity drug.

For Arena to improve, it needs to get its Belviq launch off to a good start. With pre-approved status from health insurer Aetna (NYSE: AET  ) , the company should avoid problems that other start-ups have had in launching sales of new products. That'll give Belviq the best chance to maximize profits for Arena when it becomes available.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

Click here to add Arena Pharmaceuticals to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.


Read/Post Comments (6) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On January 09, 2013, at 10:35 AM, RSRdriver wrote:

    The better question is- has Motley Fool become the perfect platform for a group of system abusing and SEC law breaking pumpers?

    Everyone that matters knows Belviq is useless and the company is going nowhere fiscally. Yet, these pump articles continue to show up.

    When will Motley Fool and Seeking Alpha wake up and see they are losing cred as a result of allowing this abuse to continue.

  • Report this Comment On January 09, 2013, at 1:49 PM, feelinIrie wrote:

    Driver You can keep making all the comments Against Arena and the responses all you, but Realize they're libelous and people are watching these boards.

    If you feel you need to take action against these articles and what the content is then I suggest you do that otherwise Just realize every Arena short is in serious trouble in this near future.

    As for Belviq being useless and problems with it, I suggest you take that up with the FDA.

  • Report this Comment On January 10, 2013, at 5:52 AM, RSRdriver wrote:

    Look, everyone knows how this stock achieved it's highs. The Areniac army is not soft in their ways. The only thing left is to round up the leaders.

    Anyone can go to level2 and see the results of the combination of a buyout rumor and 2 or 300 controlled ask/bid placements. To deny that this and the obvious organised attacks and pump festivals have not happened is ridiculous.

    What should be more important to "longs" (hah) like yourself is that the party is over. If last nights Arena presentation didn't wake you up, you people really are ARNA Zombies!

    You have nothing to look forward to and all the organised BS in the world won't help from now on because now, it's all about the drug and we all know what you have there.

  • Report this Comment On January 10, 2013, at 2:02 PM, feelinIrie wrote:

    Over? The groundwork was just Again put out in front of you last night and shorts have very time left until EU approval.

    Wait until institutional find nearest to 70% during the next report .

    The clock is ticking on all arena shorts you should cover.

  • Report this Comment On January 10, 2013, at 2:09 PM, RSRdriver wrote:

    If that is what last nights Arena report left you with then what can anyone say.

    By the way, what color is the sky in your world?

  • Report this Comment On January 10, 2013, at 2:18 PM, CorruptedSoul wrote:

    RSRdriver- just cover and be happy son.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2186957, ~/Articles/ArticleHandler.aspx, 12/22/2014 11:29:44 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement